Trial Profile
Phase, 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Given by Three Dosing Paradigms for the Reduction of Localized Subcutaneous Fat in the Submental Area
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2019
Price :
$35
*
At a glance
- Drugs Deoxycholic acid (Primary)
- Indications Subcutaneous fat disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kythera Biopharmaceuticals
- 29 May 2015 No of arms changed from 4 to 6 as per ClinicalTrials.gov record.
- 18 Jun 2014 New trial record